Despite the POLARIX trial showing greater benefit for Pola-R-CHP in non-GCB DLBCL, experts don't use this biomarker for treatment decisions. The community's IHC-based testing is considered too discordant with the trial's GEP method to be clinically reliable.

For limited-stage DLBCL, treatment decisions have evolved beyond a simple bulky vs. non-bulky assessment. The NCCN now uses the stage-modified IPI (SMIPI) score. A low score allows for abbreviated chemotherapy, while a high score mandates a more aggressive, advanced-stage treatment pathway regardless of tumor bulk.

The 5-year follow-up of the Polarix trial revealed an unexpected overall survival benefit for patients with the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma. This post-hoc finding suggests the drug's efficacy is not uniform and is most pronounced in this historically harder-to-treat patient group, challenging initial interpretations of the data.

The traditional "germinal center" (GC) classification for DLBCL is overly simplistic. Molecular analysis reveals distinct subtypes within GC, such as "dark zone" and "light zone" signatures, which have different prognoses and responses to targeted therapies like polatuzumab.

Experts view R-mini-CHOP, the standard for older/unfit DLBCL patients, as a poor benchmark that urgently needs to be replaced. Promising chemo-free or chemo-light regimens, like the R-Polo-Glofitamab combination, are seen as the future, aiming to improve outcomes in this vulnerable population without harsh toxicities.

While the first-line Polarix trial suggested Polatuzumab's benefit was greater in ABC-subtype DLBCL, the Polargo trial in relapsed patients found no such difference. Both ABC and GCB subtypes benefited significantly from Polatuzumab's addition. This suggests that in the higher-risk relapse setting, overall disease risk trumps cell of origin as the key determinant of treatment benefit.

Despite NCCN guidelines placing POLE testing first in the hierarchy, many US institutions do not perform it routinely because it currently does not alter standard-of-care treatment. Clinicians often only order the send-out test when a specific clinical trial (like RAINBO) requires it to de-escalate care.

The traditional ABC/GCB classification for DLBCL is flawed. Single-cell sequencing reveals that tumors classified as one type via bulk analysis contain malignant cells of the other subtype. This underlying heterogeneity explains why the distinction is an imperfect predictor and will be replaced by more sophisticated biomarkers like T-cell exhaustion signatures.

Due to a 20% misclassification rate with the Hans algorithm for determining cell of origin, clinicians use an IPI score of 2 or greater as the primary criterion for selecting Polatuzumab-R-CHOP. This avoids potentially giving 1 in 5 patients the wrong therapy based on an imperfect biomarker.